Literature DB >> 14961052

Topical application of a Rho-kinase inhibitor in rats causes penile erection.

Y Dai1, K Chitaley, R C Webb, R W Lewis, T M Mills.   

Abstract

Studies from this laboratory have demonstrated that RhoA/Rho-kinase signaling mediates vasoconstriction in the penile circulation of the rat and that erection results from inhibition of this activity with Y-27632. In prior animal studies, Y-27632 was administered to the rats by intracavernous injection. To determine if topical application of the Rho-kinase inhibitor is an effective mode of delivery, Y-27632 was applied to the surface of the tunica albuginea or to the glans penis and surrounding skin in intact or castrated rats. Both sites of drug administration resulted in a marked increase in the erectile response both with and without stimulation of the autonomic innervation of the penile vasculature. Although high doses of the drug were found to reduce systemic blood pressure, topical administration of the Rho-kinase inhibitor, in appropriate doses, may have clinical value for the treatment erectile dysfunction.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14961052     DOI: 10.1038/sj.ijir.3901171

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  5 in total

Review 1.  Immunomodulatory Yersinia outer proteins (Yops)-useful tools for bacteria and humans alike.

Authors:  Benjamin Grabowski; M Alexander Schmidt; Christian Rüter
Journal:  Virulence       Date:  2017-03-15       Impact factor: 5.882

Review 2.  Hydrogen sulfide and erectile function: a novel therapeutic target.

Authors:  Roberta d'Emmanuele di Villa Bianca; Raffaella Sorrentino; Vincenzo Mirone; Giuseppe Cirino
Journal:  Nat Rev Urol       Date:  2011-04-05       Impact factor: 14.432

Review 3.  Ejaculatory disorders and lower urinary tract symptoms.

Authors:  Robert E Brannigan
Journal:  Curr Urol Rep       Date:  2004-08       Impact factor: 3.092

Review 4.  Looking to the future for erectile dysfunction therapies.

Authors:  Konstantinos Hatzimouratidis; Dimitrios G Hatzichristou
Journal:  Drugs       Date:  2008       Impact factor: 9.546

Review 5.  Future prospects in the treatment of erectile dysfunction: focus on avanafil.

Authors:  Amjad Alwaal; Raed Al-Mannie; Serge Carrier
Journal:  Drug Des Devel Ther       Date:  2011-10-18       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.